Pancreatic cancer (PC) is the most lethal tumor malignancy, the fourth leading cause of cancer- related mortality. It is expected to become the second-leading cause of cancer-related mortality in North America and Western Europe by 2030.1 The average survival rate is 5 months after patients receive a diagnosis.1 Of the PCs, pancreatic ductal adenocarcinoma (PDAC) is the most common, comprising 90% to 95% of PCs, and is an aggressive malignancy with a poor prognosis.1,2 According to Andrew S. Barbas, MD, a kidney/pancreas transplant surgeon at Duke Health in Durham, NC, the scarcity of testing that can provide accurate results contributes to diagnoses in the advanced stages of the disease and consequently to poor prognoses. Read more . . .
A promising push for biomarkers in pancreatic cancer could generate new prognostic and predictive tools for clinicians. However, more research is needed to develop optimal methods for earlier identification of patients with one of the deadliest malignancies.